Profil
Sherron Kell worked as a Senior Vice President of Clinical Development at Provention Bio, Inc. from 2019 to 2021.
Prior to this, Kell obtained a graduate degree from The University of Alabama at Birmingham and an MBA from The University of Alabama School of Medicine.
Anciens postes connus de Sherron Kell
| Sociétés | Poste | Fin |
|---|---|---|
| PROVENTION BIO, INC. | Corporate Officer/Principal | 17/11/2021 |
Formation de Sherron Kell
| The University of Alabama School of Medicine | Masters Business Admin |
| The University of Alabama at Birmingham | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
